Prurigo Nodularis is skin disease that causes hard and itchy lumps on skin, which usually appears on the arms or legs. Prurigo nodularis is a rare disease and currently, the treatment of the disease is still in research and development process. Treatments may include topical, oral, and intralesional corticosteroids; phototherapy; antihistamines; anxiolytics; opiate receptor antagonists; and thalidomide.
Market Dynamics
Key players are focusing on product approvals to strengthen their position in the global Prurigo nodularis therapeutics market. For instance, in October 2020, Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company announced that the U.S. Food and Drug Administration has granted Breakthrough Therapy designation to its Vixarelimab drug for the treatment of pruritus associated with prurigo nodularis.
Key features of the study:
- This report provides in-depth analysis of the global prurigo nodularis therapeutics market, provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2021–2028), considering 2020 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global prurigo nodularis therapeutics market based on the following parameters – Company Highlights, Products Portfolio, Key Highlights, Financial Performance, Strategies
- Key companies covered as a part of this study include Bayer AG, GlaxoSmithKline Plc., Johnson & Johnson Services, Inc., Sanofi SA, Takeda Pharmaceutical Company Limited, Novartis AG, Celgene Corporation, VYNE Therapeutics Inc., Trevi Therapeutics Inc., Galderma SA, Pfizer Inc., Teva Pharmaceutical Industries Ltd., and Merck & Co. Inc.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics.
- The global Prurigo nodularis therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global prurigo nodularis therapeutics market.
Detailed Segmentation:
- Global Prurigo Nodularis Therapeutics Market, By Product Type:
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- Global Prurigo Nodularis Therapeutics Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Prurigo Nodularis Therapeutics Market, By Region:
- North America
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Latin America
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- Germany
- U.K.
- France
- Italy
- Spain
- Russia
- Rest of Europe
- Asia Pacific
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- GCC
- Israel
- Rest of Middle East
- Africa
- By Product Type
- Corticosteroids
- Capsaicin Cream
- Antihistamines
- Anticonvulsants
- Others
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country
- South Africa
- Central Africa
- North Africa
- Company Profiles
- Bayer AG *
- Company Overview
- Product Portfolio
- Financial Overview
- Key Highlights
- Market Strategies
- GlaxoSmithKline Plc.
- Johnson & Johnson Services, Inc.
- Sanofi SA
- Takeda Pharmaceutical Company Limited
- Novartis AG
- Celgene Corporation
- VYNE Therapeutics Inc.
- Trevi Therapeutics Inc.
- Galderma SA
- Pfizer Inc.
- Teva Pharmaceutical Industries Ltd.
- Merck & Co. Inc.
“*” marked represents similar segmentation in other categories in the respective section.
